![Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial - The Lancet Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial - The Lancet](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/c711b9ec-4ace-47ed-9c4c-58207208d5b4/gr1.gif)
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial - The Lancet
![Drug Discovery News on Twitter: "#Inebilizumab effective vs #neuromyelitis optica spectrum disorder, reports #VielaBio Reduces risk of #NMOSD attack 77% vs placebo; reduces worsening from baseline, hospitalizations & lesion freq https://t.co/IiQVpXliZ9 ... Drug Discovery News on Twitter: "#Inebilizumab effective vs #neuromyelitis optica spectrum disorder, reports #VielaBio Reduces risk of #NMOSD attack 77% vs placebo; reduces worsening from baseline, hospitalizations & lesion freq https://t.co/IiQVpXliZ9 ...](https://pbs.twimg.com/media/EDy01uhWwAAs9Xf.jpg)
Drug Discovery News on Twitter: "#Inebilizumab effective vs #neuromyelitis optica spectrum disorder, reports #VielaBio Reduces risk of #NMOSD attack 77% vs placebo; reduces worsening from baseline, hospitalizations & lesion freq https://t.co/IiQVpXliZ9 ...
![Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial - The Lancet Neurology Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial - The Lancet Neurology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/22b89804-586c-450c-ae3c-751ac8a6b508/gr1.gif)
Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial - The Lancet Neurology
![AstraZeneca's potential drug for neuromyelitis optica spectrum disorder receives EU orphan designation - European Pharmaceutical Review AstraZeneca's potential drug for neuromyelitis optica spectrum disorder receives EU orphan designation - European Pharmaceutical Review](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/neuromyelitis-optica-spectrum-disorder.jpg)
AstraZeneca's potential drug for neuromyelitis optica spectrum disorder receives EU orphan designation - European Pharmaceutical Review
Public summary of opinion on orphan designation Inebilizumab for the treatment of neuromyelitis optica spectrum disorders
![Medi-Cal's shift to prison labor for prescription eyewear could collapse local care system, experts warn | News | San Luis Obispo | New Times San Luis Obispo Medi-Cal's shift to prison labor for prescription eyewear could collapse local care system, experts warn | News | San Luis Obispo | New Times San Luis Obispo](https://media1.fdncms.com/ntslo/imager/u/original/10069306/news.web.sloscene.eyecare.9-3.jpg)
Medi-Cal's shift to prison labor for prescription eyewear could collapse local care system, experts warn | News | San Luis Obispo | New Times San Luis Obispo
![Pharmacotherapy for Neuromyelitis Optica Spectrum Disorders: Current Management and Future Options | SpringerLink Pharmacotherapy for Neuromyelitis Optica Spectrum Disorders: Current Management and Future Options | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs40265-018-1039-7/MediaObjects/40265_2018_1039_Fig1_HTML.png)